東京女子医科大学病院 膠原病リウマチ痛風センター
外来診療予約

最近の論文

≫過去の業績

 当センターは世界最大級のリウマチセンターであり、最新の研究活動とその結果得られる最新情報の発信は我々に与えられた重要な使命の一つと考えております。これまでにIORRAコホートや病棟で蓄積された数多くの症例を背景とした臨床研究、多彩なフィールドでの基礎研究などで多くの業績をあげており、また世界最大級の患者数を誇る施設であるため、貴重な症例の報告も積極的におこなっています。

関節リウマチ

  1. Takada H, Demoruelle MK, Deane KD, Nakamura S, Katsumata Y, Ikari K, Buckner JH, Robinson WH, Seifert JA, Feser ML, Moss L, Norris JM, Harigai M, Hsieh EWY, Holers VM, Okamoto Y. Expansion of HLA-DR Positive Peripheral Helper T and Naive B Cells in Anticitrullinated Protein Antibody-Positive Individuals At Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2024 Jul; 76(7): 1023-1035. doi: 10.1002/art.42839.
  1. Sugano E, Tanaka E, Inoue E, Honda S, Abe M, Saka K, Sugitani N, Ochiai M, Yamaguchi R, Ikari K, Harigai M. Impact of interstitial lung disease on clinical remission and unfavourable events of rheumatoid arthritis: results from the IORRA cohort. Rheumatology (Oxford). 2024 Apr; 63(4): 1022-1029. doi: 10.1093/rheumatology/kead317.
  1. Sakai R, Tanaka E, Inoue E, Harigai M. Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database. RMD Open. 2024 Jun; 10(2): e003885. doi: 10.1136/rmdopen-2023-003885.
  1. Harigai M, Tanaka E, Inoue E, Tamura N, Misaki K, Azuma T, Hirata S, Hirano F, Taniguchi Y, Mitsuhashi M, Kondo M, Oribe M, Aoki K, Kadode M, Tsuritani K, Yamanaka H. Contribution of the factors to EuroQol 5 Dimensions in rheumatoid arthritis patients achieving low disease activity/remission with abatacept treatment: Post hoc subgroup analyses of the Japanese real-world observational 'ORIGAMI' study. Mod Rheumatol. 2024 Jul; 34(4): 686-692. doi: 10.1093/mr/road082.
  1. Higuchi T, Tanaka E, Inoue E, Abe M, Saka K, Sugano E, Sugitani N, Higuchi Y, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M. Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease-modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data. Mod Rheumatol. 2024 Jul; 34(4): 693-699. doi: 10.1093/mr/road066.
  1. Sugitani N, Tanaka E, Inoue E, Abe M, Sugano E, Saka K, Ochiai M, Higuchi Y, Yamaguchi R, Sugimoto N, Ikari K, Nakajima A, Yamanaka H, Harigai M. Unincreased mortality of patients with early rheumatoid arthritis compared to the general population in the past 17 years: Analyses from the IORRA cohort. Mod Rheumatol. 2024 Feb; 34(2): 322-328. doi: 10.1093/mr/road020.
  1. Furuya T, Inoue E, Tanaka E, Yamanaka H, Harigai M. Prevalence of high and low serum alkaline phosphatase levels and the associated factors in patients with rheumatoid arthritis: Results from the IORRA cohort study. Mod Rheumatol. 2024 Oct; 34(6): 1277-1280. doi: 10.1093/mr/roae025.
  1. Harigai M, Tanaka E, Inoue E, Sakai R, Sugitani N, Toyoizumi S, Sugiyama N, Yamanaka H. Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry. Rheumatol Ther. 2024 Oct; 11(5): 1181-1195. doi: 10.1007/s40744-024-00689-8.
  1. Tanaka H, Okada Y, Nakayamada S, Miyazaki Y, Sonehara K, Namba S, Honda S, Shirai Y, Yamamoto K, Kubo S, Ikari K, Harigai M, Sonomoto K, Tanaka Y. Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping. Ann Rheum Dis. 2024 Jan; 83(2): 242-252. doi: 10.1136/ard-2023-224537.
  1. Nakayama Y, Nagata W, Takeuchi Y, Fukui S, Fujita Y, Hosokawa Y, Ueno M, Ono K, Sumitomo S, Tabuchi Y, Nakanishi Y, Saito S, Ikeuchi H, Kawamori K, Sofue H, Doi G, Minami R, Hirota T, Minegishi K, Maeshima K, Motoyama R, Nakamura S, Suzuki S, Nishioka N, Wada TT, Onishi A, Nishimura K, Watanabe R, Yanai R, Kida T, Nishiwaki H, Yajima N, Kaneko Y, Tanaka E, Kawahito Y, Harigai M. Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2024 Oct; 34(6): 1079-1094. doi: 10.1093/mr/roae049.
  1. Kojima M, Sugihara T, Kawahito Y, Kojima T, Kaneko Y, Ishikawa H, Abe A, Matsui K, Hirata S, Kishimoto M, Tanaka E, Morinobu A, Hashimoto M, Matsushita I, Hidaka T, Matsui T, Nishida K, Asai S, Ito H, Harada R, Harigai M. Consensus statement on the management of late-onset rheumatoid arthritis. Mod Rheumatol. 2024 Oct; 34(6): 1095-1102. doi: 10.1093/mr/roae011.
  2. Sugihara T, Kawahito Y, Kaneko Y, Tanaka E, Yanai R, Yajima N, Kojima M, Harigai M. Systematic review for the treatment of older rheumatoid arthritis patients informing the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol. 2024 Aug; 34(5): 867-880. doi: 10.1093/mr/roae026.
  1. Misaki K, Tamura N, Azuma T, Shinoda K, Tanaka M, Fujiwara H, Tsuboi H, Kasama T, Yoshimi R, Hanyu T, Kusaka Y, Hirao M, Onishi M, Uchino A, Izumiyama T, Yang KS, Ogawa N, Matsui K, Kurasawa K, Kawaai S, Yasuoka H, Okumura N, Ueda Y, Tanaka E, Inoue E, Tsuritani K, Matsumoto S, Yamanaka H, Harigai M. Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI). Mod Rheumatol. 2024 Feb; 34(2): 297-306. doi: 10.1093/mr/road045.
  1. Misaki K, Tanaka E, Inoue E, Tamura N, Hirano F, Taniguchi Y, Sato H, Naniwa T, Oshikawa H, Yoshitama T, Takakubo Y, Suzuki Y, Himeno S, Tsuritani K, Matsumoto S, Yamanaka H, Harigai M. Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI). Mod Rheumatol. 2024 Dec; 35(1): 17-26. doi: 10.1093/mr/roae043.
  1. Takanashi S, Kaneko Y, Kawahito Y, Kida T, Sugihara T, Kojima T, Harada R, Ishitoku M, Hirata S, Hashimoto M, Hidaka T, Abe A, Ishikawa H, Ito H, Kishimoto M, Matsui K, Matsui T, Matsushita I, Onishi A, Morinobu A, Nishida K, Asai S, Tanaka E, Harigai M, Kojima M. A Preliminary Survey of Rheumatologists on the Management of Late-onset Rheumatoid Arthritis in Japan. Intern Med. 2024 Dec; 63(24): 3299-3306. doi: 10.2169/internalmedicine.3288-23.
  1. Sugihara T, Tanaka E, Matsui T. Low-Dose Glucocorticoids in Older Patients with Rheumatoid Arthritis: What Does the Evidence Say? Drugs Aging. 2024 Aug; 41(8): 641-652. Doi: 10.1007/s40266-024-01133-w.

 

SLE

  1. Katsumata Y, Inoue E, Harigai M, Cho J, Louthrenoo W, Hoi A, Golder V, Lau CS, Lateef A, Chen YH, Luo SF, Wu YJ, Hamijoyo L, Li Z, Sockalingam S, Navarra S, Zamora L, Hao Y, Zhang Z, Chan M, Oon S, Ng K, Kikuchi J, Takeuchi T, Goldblatt F, O'Neill S, Tugnet N, Law AHN, Bae SC, Tanaka Y, Ohkubo N, Kumar S, Kandane-Rathnayake R, Nikpour M, Morand EF; Asia-Pacific Lupus Collaboration. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis. 2024 Jul; 83(8): 998-1005. doi: 10.1136/ard-2023-225369.
  1. Moriyama R, Katsumata Y, Okamoto Y, Harigai M. Upregulation of PD-1 and its ligands and expansion of T peripheral helper cells in the nephritic kidneys of lupus-prone BXSB- Yaa mice. Lupus. 2024 Jul; 33(8): 816-827. doi: 10.1177/09612033241247908.
  1. Golder V, Kandane-Rathnayake R, Li N, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake D, Chan M, Kikuchi J, Takeuchi T, Bae SC, Goldblatt F, Oon S, O'Neill S, Ng K, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Hoi A, Nikpour M, Morand EF; Asia Pacific Lupus Collaboration. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study. Lancet Rheumatol. 2024 Aug; 6(8): e528-e536. doi: 10.1016/S2665-9913(24)00121-8.
  1. Yeo AL, Kandane-Rathnayake R, Koelmeyer R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, An Y, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake BMDB, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Nikpour M, Hoi A, Leech M, Morand EF; Asia Pacific Lupus Collaboration. SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus-an analysis of anti-double-stranded DNA monitoring. Rheumatology (Oxford). 2024 Feb; 63(2): 525-533. doi: 10.1093/rheumatology/kead231.
  1. Golder V, Kandane-Rathnayake R, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Hao Y, Zhang Z, Basnayake BMDB, Chan M, Kikuchi J, Takeuchi T, Bae SC, Oon S, O'Neill S, Goldblatt F, Ng KPL, Law A, Tugnet N, Kumar S, Tee C, Tee M, Ohkubo N, Tanaka Y, Lau CS, Nikpour M, Hoi A, Morand EF; Asia Pacific Lupus Collaboration. Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus. J Rheumatol. 2024 Aug; 51(8): 790-797. doi: 10.3899/jrheum.2023-0900.
  1. Hao Y, Hansen D, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra S, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, Zhang Z, Chan M, Kikuchi J, Takeuchi T, Bae SC, Goldblatt F, O'Neill S, Ng K, Basnayake BMDB, Tugnet N, Tanaka Y, Lau CS, Li N, Golder V, Hoi A, Kandane-Rathnayake R, Morand E, Oon S, Nikpour M. Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus. Lupus Sci Med. 2024 Sep; 11(2): e001217. doi: 10.1136/lupus-2024-001217.
  1. de Luca Montes RA, Huq M, Godfrey T, Oon S, Calderone A, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Jan Wu YJ, Golder V, Lateef A, Navarra SV, Zamora L, Hamijoyo L, Sockalingam S, An Y, Li Z, Katsumata Y, Harigai M, Chan M, Goldblatt F, O'Neill S, Lau CS, Cho J, Hoi A, Karyekar CS, Morand EF, Nikpour M. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study. Adv Rheumatol. 2024 May; 64(1): 38. doi: 10.1186/s42358-024-00366-y.

 

全身性強皮症

  1. Hirose H, Higuchi T, Takagi K, Tochimoto A, Ichimura Y, Harigai M, Kawaguchi Y. Seasonal fluctuation of serum Krebs von den Lungen-6 levels in systemic sclerosis-associated interstitial lung disease. Int J Rheum Dis. 2024 Jul; 27(7): e15254. doi: 10.1111/1756-185X.15254.
  1. Hirose H, Higuchi T, Takagi K, Tochimoto A, Ichimura Y, Katsumata Y, Harigai M, Kawaguchi Y. Association of elevated serum carbohydrate antigen 19-9 levels with extensive interstitial lung disease in patients with systemic sclerosis: A cross-sectional study. Int J Rheum Dis. 2024 Jan; 27(1): e14978. doi: 10.1111/1756-185X.14978.
  1. Ishikawa Y, Tanaka N, Asano Y, Kodera M, Shirai Y, Akahoshi M, Hasegawa M, Matsushita T, Saito K, Motegi SI, Yoshifuji H, Yoshizaki A, Kohmoto T, Takagi K, Oka A, Kanda M, Tanaka Y, Ito Y, Nakano K, Kasamatsu H, Utsunomiya A, Sekiguchi A, Niiro H, Jinnin M, Makino K, Makino T, Ihn H, Yamamoto M, Suzuki C, Takahashi H, Nishida E, Morita A, Yamamoto T, Fujimoto M, Kondo Y, Goto D, Sumida T, Ayuzawa N, Yanagida H, Horita T, Atsumi T, Endo H, Shima Y, Kumanogoh A, Hirata J, Otomo N, Suetsugu H, Koike Y, Tomizuka K, Yoshino S, Liu X, Ito S, Hikino K, Suzuki A, Momozawa Y, Ikegawa S, Tanaka Y, Ishikawa O, Takehara K, Torii T, Sato S, Okada Y, Mimori T, Matsuda F, Matsuda K, Amariuta T, Imoto I, Matsuo K, Kuwana M, Kawaguchi Y, Ohmura K, Terao C. GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region. Nat Commun. 2024 Jan; 15(1): 319. doi: 10.1038/s41467-023-44541-z.
  1. Uesugi-Uchida S, Fujimoto M, Asano Y, Endo H, Goto D, Jinnin M, Kawaguchi Y, Tanaka S, Tokunaga T, Makino K, Matsushita T, Motegi SI, Yoshizaki A, Sato S, Hasegawa M. Predictors of clinical features in early-onset severe systemic sclerosis: An analysis from a multicenter prospective observational Japanese cohort. J Dermatol. 2024 Oct; 51(10): 1290-1297. doi: 10.1111/1346-8138.17403.

 

皮膚筋炎/多発筋炎

  1. Ichimura Y, Konishi R, Shobo M, Tanaka R, Kubota N, Kayama H, Takeda K, Nomura T, Fujimoto M, Okiyama N. Autoimmunity against melanoma differentiation-associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice. Proc Natl Acad Sci U S A. 2024 Apr; 121(16): e2313070121. doi: 10.1073/pnas.2313070121.
  1. Tsuji H, Nakashima R, Yasumi T, Sasai T, Ichimura Y, Shirakashi M, Onizawa H, Hiwa R, Kitagori K, Akizuki S, Onishi A, Yoshifuji H, Tanaka M, Okiyama N, Mimori T, Morinobu A. Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2024 Oct; 68: 152530. doi: 10.1016/j.semarthrit.2024.152530.
  1. Okiyama N, Konishi R, Ichimura Y. Murine models of idiopathic inflammatory myopathies. J Dermatol. 2024 Jul; 51(7): 914-919. doi: 10.1111/1346-8138.17142.
  1. Konishi R, Ichimura Y, Tanaka R, Miyahara H, Okune M, Miyamoto M, Hara M, Iwabuchi A, Takada H, Nakagishi Y, Mizuta M, Kaneko S, Shimizu M, Morio T, Nishino I, Nomura T, Okiyama N. Possible correlation between serum interleukin-8 levels and the activity of myositis in anti-NXP2 antibody-positive dermatomyositis. Immunol Med. 2024 Jun; 47(2): 100-105. doi: 10.1080/25785826.2023.2300553.

 

血管炎

  1. Harigai M, Miyamae T, Hashimoto H, Umetsu K, Yamashita K, Nakaoka Y. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan. Mod Rheumatol. 2024 Jul 6; 34(4): 775-783. doi: 10.1093/mr/road074.
  1. Kawazoe M, Nanki T, Saeki K, Ishikawa H, Nakamura Y, Kawashima S, Ito S, Kodera M, Konda N, Kaname S, Harigai M. Nationwide epidemiological survey of polyarteritis nodosa in Japan in 2020. Mod Rheumatol. 2024 Oct; 34(6): 1284-1287. doi: 10.1093/mr/roae010.

 

小児リウマチ科

  1. Miyamae T, Tani Y, Inoue E, Tomohiro K, Harigai M. Interleukin-18 as a crucial cytokine in chronic arthritic systemic juvenile idiopathic arthritis. Int J Rheum Dis. 2024 Mar; 27(3): e15105. doi: 10.1111/1756-185X.15105.
  1. Miyamoto T, Izawa K, Masui S, Yamazaki A, Yamasaki Y, Matsubayashi T, Shiraki M, Ohnishi H, Yasumura J, Kawabe T, Miyamae T, Matsubara T, Arakawa N, Ishige T, Takizawa T, Shimbo A, Shimizu M, Kimura N, Maeda Y, Maruyama Y, Shigemura T, Furuta J, Sato S, Tanaka H, Izumikawa M, Yamamura M, Hasegawa T, Kaneko H, Nakagishi Y, Nakano N, Iida Y, Nakamura T, Wakiguchi H, Hoshina T, Kawai T, Murakami K, Akizuki S, Morinobu A, Ohmura K, Eguchi K, Sonoda M, Ishimura M, Furuno K, Kashiwado M, Mori M, Kawahata K, Hayama K, Shimoyama K, Sasaki N, Ito T, Umebayashi H, Omori T, Nakamichi S, Dohmoto T, Hasegawa Y, Kawashima H, Watanabe S, Taguchi Y, Nakaseko H, Iwata N, Kohno H, Ando T, Ito Y, Kataoka Y, Saeki T, Kaneko U, Murase A, Hattori S, Nozawa T, Nishimura K, Nakano R, Watanabe M, Yashiro M, Nakamura T, Komai T, Kato K, Honda Y, Hiejima E, Yonezawa A, Bessho K, Okada S, Ohara O, Takita J, Yasumi T, Nishikomori R; Japan CAPS Working Group. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey. Arthritis Rheumatol. 2024 Jun; 76(6): 949-962. doi: 10.1002/art.42808.
  1. Sada KE, Miyamae T, Kaneko K, Isojima S, Ichinose K, Matsushita M, Oku K, Iwata Y, Fujio K, Murashima A, Tanaka Y, Nakajima A. Effects of cyclophosphamide administration on ovarian dysfunction in pediatric patients with connective tissue diseases: A systematic scoping review. Mod Rheumatol. 2024 Dec 25; 35(1): 88-93. doi: 10.1093/mr/roae060.
  1. Fusama M, Nakahara H, Miyamae T, Mori M, Urata Y, Kawahata K, Kawahito Y, Kojima M, Sugihara T, Hashimoto M, Murashima A, Yajima N, Matsui T. Challenges nurses face in providing care for patients with juvenile idiopathic arthritis. Mod Rheumatol. 2024 Dec; 35(1): 185-193. doi: 10.1093/mr/roae041.
  1. Abe Y, Fujii T, Miyawaki Y, Sugihara T, Uchida HA, Maejima Y, Watanabe Y, Hashimoto T, Miyamae T, Nakaoka Y, Harigai M, Tamura N. Real-world clinical decisions of physicians in the management of Takayasu arteritis and giant cell arteritis in Japan: A cross-sectional web questionnaire survey. Mod Rheumatol. 2024 Oct; 34(6): 1194-1201. doi: 10.1093/mr/roae034.
  1. Hatano M, Yajima N, Yanai R, Ishii S, Tsujimoto Y, Azuma T, Atsumi T, Kaneko Y, Kameda H, Kuwana M, Tanaka Y, Nakagawa S, Nakajima A, Hiramatsu Y, Fujita D, Miyamae T, Murashima A. Development of quality indicators for pregnancy and childbirth in patients with systemic lupus erythematosus. Mod Rheumatol. 2024 Oct; 34(6): 1170-1177. doi: 10.1093/mr/roae029.
  1. Ebato T, Kishi T, Akamine K, Nozawa T, Imagawa T, Bando Y, Miyamae T. Evaluation of medication withdrawal in patients with non-systemic juvenile idiopathic arthritis in Japan using a web-based survey. Mod Rheumatol. 2024 Oct; 34(6): 1231-1237. doi: 10.1093/mr/roae016.
  1. Fusama M, Nakahara H, Gregg M, Kuroe Y, Urata Y, Kawahata K, Kawahito Y, Kojima M, Sugihara T, Hashimoto M, Miyamae T, Murashima A, Mori M, Yajima N, Matsui T. Challenges faced by nurses engaged in rheumatology care in Japan. Mod Rheumatol. 2024 Jul; 34(4): 711-719. doi: 10.1093/mr/road079.
  1. Isojima S, Yajima N, Yanai R, Miura Y, Fukuma S, Kaneko K, Fujio K, Oku K, Matsushita M, Miyamae T, Wada T, Tanaka Y, Kaneko Y, Nakajima A, Murashima A. Physician approval for pregnancy in patients with systemic lupus erythematosus showing only serological activity: A vignette survey study. Mod Rheumatol. 2024 Mar; 34(3): 509-514. doi: 10.1093/mr/road049.

 

 

 リウマチ整形

  1. Mochizuki T, Koenuma N, Yano K, Ikari K, Hiroshima R, Okazaki K. Intensive treatment for the progression of joint damage in rheumatoid arthritis patients with low disease activity or remission. Mod Rheumatol. 2024 Feb; 34(2): 329-333. doi: 10.1093/mr/road041.
  1. Yano K, Ikari K, Shiraki E, Midorikawa M, Maeda M, Kubo K, Kuwahara Y, Okazaki K. Short-term efficacy and limitations of foot care in patients with rheumatoid arthritis. Mod Rheumatol. 2024 Oct; 34(6): 1149-1152. doi: 10.1093/mr/roae012.
  1. Nakayama M, Furuya T, Inoue E, Tanaka E, Ikari K, Yamanaka H, Harigai M. Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study. Clin Rheumatol. 2024 Jan; 43(1): 521-526. doi: 10.1007/s10067-023-06779-2.
  1. Mochizuki T, Yano K, Ikari K, Okazaki K. Effects of Locomotion Training on Bone Mineral Density in Patients with Rheumatoid Arthritis. Prog Rehabil Med. 2024 Jun: 9: 20240022. doi: 10.2490/prm.20240022.
  1. Koenuma N, Ikari K, Oh K, Iwakura N, Okazaki K. Long-Term Implant Fracture Rates Following Silicone Metacarpophalangeal Joint Arthroplasty in Rheumatoid Arthritis. J Hand Surg Am. 2024 May; 49(5): 443-449. doi: 10.1016/j.jhsa.2024.01.009.
  1. Tominaga A, Ikari K, Yamada A, Yano K, Okazaki K. Outcomes of Joint-Preserving Surgery for Forefoot Deformities in Patients With Rheumatoid Arthritis. Foot Ankle Int. 2024 Mar; 45(3): 261-271. doi: 10.1177/10711007241226898.
  1. Mochizuki T, Otani N, Ando M, Hiroshima R, Yano K, Ikari K, Okazaki K. Imaging using diffusion-weighted whole-body imaging with background signal suppression for methotrexate-associated lymphoproliferative disorder: A case report. Mod Rheumatol Case Rep. 2024 Dec: rxae078. doi: 10.1093/mrcr/rxae078. [Online ahead of print.]